Physician profile
Ellen A Neylon
NPI 1174894554
$138,413.10
in general payments reported to CMS, 2019-2025
50 companies · $21K in 2025
The $21K reported for 2025 was more than what 96% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2021: $17K · 2022: $21K · 2023: $48K · 2024: $32K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Travel and Lodging: $26K · Food and Beverage: $14K · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,200.00 |
| Travel and Lodging | $25,969.66 |
| Food and Beverage | $13,857.83 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $86,874.06 | 2021-2025 | Mounjaro, Jardiance, Verzenio |
| Novo Nordisk INC | $35,103.11 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Eli Lilly and Company | $4,845.86 | 2022-2025 | |
| Abbott Laboratories | $2,061.02 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $1,242.76 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $1,061.52 | 2021-2025 | Korlym |
| Horizon Therapeutics Plc | $750.61 | 2021-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $442.14 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.67 | 2021-2025 | Jardiance |
| Chiesi USA, INC. | $408.88 | 2024-2025 | Myalept, Mycapssa |
| Ascendis Pharma Endocrinology INC | $346.65 | 2024-2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $324.53 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $316.05 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $302.07 | 2021-2023 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $292.19 | 2021-2025 | Repatha, Tepezza, Evenity |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $285.96 | 2023-2025 | Crysvita |
| Sanofi-Aventis U.S. LLC | $277.21 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $224.63 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $217.87 | 2022-2023 | Myalept |
| Alexion Pharmaceuticals, INC. | $207.63 | 2023-2024 | Strensiq |
| Recordati_rare_diseases_inc. | $197.91 | 2024-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $197.25 | 2023-2025 | Minimed 780g |
| Chiasma, INC. | $181.91 | 2021 | |
| Insulet Corporation | $179.85 | 2022 | |
| Madrigal Pharmaceuticals | $154.99 | 2024-2025 | Resmetirom, Rezdiffra |
| Nestle Healthcare Nutrition INC. | $151.03 | 2021 | |
| Averitas Pharma INC. | $139.99 | 2025 | Qutenza |
| Incyte Corporation | $124.98 | 2025 | Zynyz |
| Biohaven Pharmaceutical Holding Company LTD. | $124.49 | 2022 | |
| Esperion Therapeutics, INC. | $123.47 | 2022-2024 | Nexletol |
| Pharmacosmos Therapeutics INC. | $121.19 | 2024 | Monoferric |
| Deciphera Pharmaceuticals INC. | $119.30 | 2024 | Qinlock |
| Beta Bionics, INC. | $112.83 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Mannkind Corporation | $73.97 | 2022-2025 | Afrezza |
| Ascensia Diabetes Care US INC. | $50.15 | 2022-2025 | |
| Soleno Therapeutics, INC. | $48.16 | 2025 | Vykat Xr |
| Radius Health, INC. | $36.56 | 2022-2023 | Tymlos |
| Pfizer INC. | $32.93 | 2023 | |
| Almatica Pharma LLC | $32.10 | 2025 | Teriparatide |
| Ionis Pharmaceuticals, INC. | $29.29 | 2025 | Tryngolza |
| Boston Scientific Corporation | $27.52 | 2025 | General - Pain Management |
| Amneal Pharmaceuticals LLC | $26.38 | 2021-2022 | |
| Lifescan, INC. | $24.75 | 2021 | |
| Embecta Corp. | $21.60 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sequel Med Tech, LLC | $19.79 | 2025 | Twiist |
| Nevro Corp. | $19.03 | 2023 | Senza |
| Endo Pharmaceuticals INC. | $16.77 | 2022 | |
| Ibsa Pharma INC. | $16.60 | 2023 | Tirosint, Licart |
| Antares Pharma, INC. | $11.89 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,922.18 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Neylon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.